Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA4 | P22748 | 2/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163455 | 0.85 | RAB9A (0.63) | LMNACA2CA1ALDH1A1TSHR | |
| SCHEMBL10860489 | 0.83 | LMNA (0.55) | LMNACA2CA12CA1CA9 | |
| SCHEMBL4070721 | 0.83 | LMNA (0.55) | LMNACA2CA12CA1CA9 | |
| SCHEMBL8251507 | 0.82 | LMNA (0.53) | LMNACA2CA12CA1CA9 | |
| SCHEMBL11307758 | 0.80 | LMNA (0.57) | LMNACA2CA12CA1CA9 | |
| SCHEMBL5880397 | 0.80 | CA2 (0.68) | CA2CA12CA1CA9CA4 | |
| SCHEMBL31055696 | 0.80 | CA2 (0.68) | CA2CA12CA1CA9CA4 | |
| SCHEMBL29405930 | 0.79 | ALDH1A1 (0.69) | LMNACA2CA12CA1CA9 | |
| SCHEMBL2481197 | 0.79 | ALDH1A1 (0.54) | LMNAALDH1A1TDP1RAB9ANPC1 | |
| SCHEMBL2480051 | 0.79 | ALDH1A1 (0.69) | LMNACA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | claimed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12286436-B2 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | King Faisal University (SA) | 2025-04-29 | — | — | US | disclosed |
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2025-04-08 | — | — | US | disclosed |
| US-20250092048-A1 | PYRIMIDO[4,5-B]INDOLE COMPOUNDS AS CK2 INHIBITORS | UNIV KING FAISAL (SA) | 2025-03-20 | — | — | US | disclosed |
| US-12240851-B1 | Pyrido[3′,4′:4,5]pyrrolo[3,2-c]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2025-03-04 | — | — | US | disclosed |
| US-20250066362-A1 | PYRIDO[3',4':4,5]PYRROLO[3,2-C]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | King Faisal University (SA) | 2025-02-27 | — | — | US | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| WO-1997037646-A1 | CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| EP-0372315-B1 | Reactive dyes based on copper formazane | BASF AG (DE) | 1994-01-26 | — | — | EP | disclosed |
| US-5149789-A | Triazine dyes | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-22 | — | — | US | disclosed |
| US-5041540-A | For dyeing or printing hydroxyl- or nitrogen-containing substrates | BASF AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0391264-A1 | Reactive dyes with two or three halogen-N-heterocycles as reactive groups | BASF Aktiengesellschaft (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0372315-A1 | Reactive dyes based on copper formazane | BASF Aktiengesellschaft (DE) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092048-A1 | PYRIMIDO[4,5-B]INDOLE COMPOUNDS AS CK2 INHIBITORS | SKP2, CDK2, CSNK2A1 | LMNA 4391/4885CA2 969/4885CA12 3544/4885 |
| US-20250066362-A1 | PYRIDO[3',4':4,5]PYRROLO[3,2-C]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORS | CKS2, CDK2, PNKP | LMNA 2543/4885CA2 1164/4885CA12 4068/4885 |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | SCN8A, SCN1A, SCN2A | LMNA 1580/4885CA2 613/4885CA12 3752/4885 |
| US-12240851-B1 | Pyrido[3′,4′:4,5]pyrrolo[3,2-c]naphthyridine compounds as CK2 inhibitors | CKS2, CDK2, PNKP | LMNA 2500/4885CA2 1181/4885CA12 4104/4885 |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN1B | LMNA 916/4885CA2 165/4885CA12 2568/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3643/4885CA2 3233/4885CA12 4759/4885 |
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | CKS2, CSNK1G1, CSNK2A3 | LMNA 2168/4885CA2 1380/4885CA12 4140/4885 |
| US-12286436-B2 | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors | SKP2, CDK2, CSNK2A1 | LMNA 4535/4885CA2 974/4885CA12 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.